Ras inhibitors are drugs that target Ras proteins, crucial in cell signaling pathways. The future sees potential applications in treating various cancers.

IASO Bio alongside Innovent unveiled fresh Equecabtagene Autoleucel (FUCASO®) findings for those affected by multiple myeloma, during the 2023 ASH conference.

Adverse drug reaction (ADR) refers to the harmful reactions of qualified drugs that are unrelated to the purpose of medication under normal usage and dosage.

Qilu Pharma Releases Initial Clinical Data on New Dual-Target Antibody QLS31905 During ESMO Immuno-Oncology Meeting.

Proteasome inhibitors are a type of medication that interfere with the activity of proteasomes.

Electra Therapeutics unveils initial study results from their active Phase 1b trial of ELA026 designed to combat secondary HLH (hemophagocytic lymphohistiocytosis)

When patients take atropine to treat gastrointestinal pain, it is easy to produce side effects of blurred vision.

Agenus Inc., an innovator in immune-modulatory cancer treatments, announced reaching its second milestone in the global licensing agreement with Bristol Myers Squibb for BMS-986442, a bispecific TIGIT antibody with improved Fc functionality.

RANKL inhibitors are drugs that target the RANKL protein, crucial in bone metabolism. The future sees potential applications in treating bone-related disorders and certain cancers.

Atara Biotherapeutics Unveils Encouraging Early Research Results for ATA3431, an Innovative Off-the-Shelf CAR Therapy Aimed at CD20 and CD19, at the 65th Annual Session of ASH.

The inducing factors of adverse drug reactions include non drug factors and drug factors.

The FDA has approved Pfizer’s review request for marstacimab, a hemophilia A/B treatment for non-inhibitor patients.